Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma.

作者信息

Buchali K, Correns H J, Schuerer M, Schnorr D, Lips H, Sydow K

机构信息

Klinik für Nuklearmedizin, Bereich Medizin (Charitè), Humboldt-Universität, Berlin, German Democratic Republic.

出版信息

Eur J Nucl Med. 1988;14(7-8):349-51. doi: 10.1007/BF00254382.

Forty-nine patients were treated with either 3 x 75 MBq 89Sr or saline as placebo. Analysis of results 1 to 3 years after therapy revealed the ineffectiveness of 89Sr to relieve pain from metastases. Unexpectedly, a higher survival rate was found after Sr application (46% vs 4% after 2 years). Covariate analysis underlines the effect of 89Sr therapy on life expectation.